全文获取类型
收费全文 | 707篇 |
免费 | 61篇 |
国内免费 | 31篇 |
专业分类
儿科学 | 21篇 |
妇产科学 | 2篇 |
基础医学 | 188篇 |
口腔科学 | 6篇 |
临床医学 | 61篇 |
内科学 | 156篇 |
皮肤病学 | 3篇 |
神经病学 | 4篇 |
特种医学 | 13篇 |
外科学 | 22篇 |
综合类 | 96篇 |
现状与发展 | 1篇 |
预防医学 | 74篇 |
眼科学 | 5篇 |
药学 | 111篇 |
中国医学 | 7篇 |
肿瘤学 | 29篇 |
出版年
2024年 | 3篇 |
2023年 | 19篇 |
2022年 | 35篇 |
2021年 | 35篇 |
2020年 | 13篇 |
2019年 | 28篇 |
2018年 | 30篇 |
2017年 | 35篇 |
2016年 | 31篇 |
2015年 | 20篇 |
2014年 | 40篇 |
2013年 | 77篇 |
2012年 | 31篇 |
2011年 | 27篇 |
2010年 | 20篇 |
2009年 | 31篇 |
2008年 | 29篇 |
2007年 | 23篇 |
2006年 | 24篇 |
2005年 | 22篇 |
2004年 | 33篇 |
2003年 | 19篇 |
2002年 | 14篇 |
2001年 | 16篇 |
2000年 | 14篇 |
1999年 | 5篇 |
1998年 | 14篇 |
1997年 | 10篇 |
1996年 | 17篇 |
1995年 | 5篇 |
1994年 | 10篇 |
1993年 | 8篇 |
1992年 | 6篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 2篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 7篇 |
1982年 | 3篇 |
1981年 | 6篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有799条查询结果,搜索用时 31 毫秒
1.
2.
新生儿重组酵母乙肝疫苗接种免疫的研究 总被引:1,自引:0,他引:1
目的:探讨重组酵母乙肝疫苗新生儿接种后抗体应答持续时间,强化复种的必要性。方法:常规对新生儿0d(出生后当天)、1月、6月接种重组酵母乙肝疫苗后检测抗体应答情况,再随机分两组,一组为强化组,一组为常规组,并随访其5年的抗体应答情况。结果:新生儿常规接种法,于12个月后有一明显抗体应答下降期(0d、1月、6月、12月),强化组乙肝表面抗体形成率高,持续时间均高于常规接种法。结论:新生儿乙肝疫苗0d、1月、6月、12月接种法有较好的远期保护效果,对现有的0d、1月、6月新生儿乙肝疫苗常规接种法,有强化接种的必要。 相似文献
3.
目的:利用粒细胞-巨噬细胞集落刺激因子(GM-CSF)作为基因佐剂,提高东部马脑炎病毒E2基因重组质粒的免疫效果.方法:分别扩增E2基因与GM-CSF基因,连接进入含有内部核糖体插入位点(IRES)的真核表达载体中,构建共表达质粒.Lipofectamine2000介导转染真核细胞BHK-21,反转录PCR检测E2和GM-CSF两个基因的转录,Western印迹法和间接免疫荧光法(IFA)检测细胞内E2基因表达产物的抗原性.通过肌肉注射免疫BALB/c小鼠,IFA法测定血清抗体效价,FACS测定免疫小鼠脾细胞中CD4 /CD8 淋巴细胞构成比,初步观察共表达质粒的免疫原性.结果:经酶切鉴定与序列测定证明重组共表达质粒中含有E2和GM-CSF两个基因且序列正确.转染细胞的反转录PCR可见E2和GM-CSF两个基因的转录.Western印迹结果可见转染细胞的裂解液在相对分子质量50 000位置有特异性条带.将转染细胞制成荧光抗原片,经IFA检测可见胞浆中出现特异荧光.免疫小鼠的最高血清抗体效价为1:160,但细胞免疫未观察到明显的提高.结论:构建的共表达质粒pE2-IRES-mGM-CSF具有良好的免疫原性,能有效刺激小鼠特异性体液免疫应答,提高了E2基因重组质粒诱导的血清抗体效价. 相似文献
4.
Wolf Szmuness Cladd E. Stevens Edward J. Harley Edith A. Zang Patricia E. Taylor Harvey J. Alter The Dialysis Vaccine Trial Group 《Journal of medical virology》1981,8(2):123-129
Three hundred thirty-six medical personnel from hemodialysis centers were treated with three doses, 20 μg each, of the Merck hepatitis B vaccine (at 0, 1, and 6 months). Within 1 month after the first injection, 41% converted to anti-HBs positivity; after the second injection the conversion rate rose to 80–90%; and after the booster, to 96–98%. The later rate remained unchanged during the 18-month follow-up period. Only 2.8% of those vaccinated did not respond to the vaccine. The patterns of immune responses to 20-μg doses were found to be exactly the same as to 40-μg doses. It is suggested that reduced doses of vaccine should be as efficacious as the larger ones. 相似文献
5.
Lee AJ Haworth C Hutchinson RM Patel R Carter R James RF 《Clinical and experimental immunology》2001,124(3):359-368
Pre-B cell acute lymphoblastic leukaemia (cALL) commonly occurs in young patients and although successful conventional therapies are available (such as cytotoxic drugs and bone marrow transplantation) for a proportion of patients (approximately 30%) these are ultimately unsuccessful. Recurrence of disease is a result of the failure of the immune system to recognize these abnormal cells and down-regulation of crucial molecules required for cognate CD4(+) T cell recognition has been postulated as a means of immune escape. In this study we show that an embryonic kidney cell line (293 cells) transfected with CD154 (40 L.1) are capable of not only maintaining the viability of primary ALL cells in culture but can also up-regulate the expression of a number of crucial molecules involved in antigen recognition. We show that 40 L.1 cell stimulation of primary ALL cell cultures can not only enhance the allogeneic and autologous MLR response to such cells but will also induce CTL effectors which are capable of lysing wild-type autologous ALL cells. It is therefore conceivable that such an approach could be used to generate an active anti-tumour response in patients, following conventional therapy, reducing the incidence of recurrence. 相似文献
6.
蛋白转导域介导BCR/ABL抗原对CML患者T细胞的活化作用 总被引:2,自引:0,他引:2
目的:研究蛋白转导域(PTD)介导的BCR/ABL抗原对慢性髓细胞白血病(CML)患者T细胞的特异性活化作用。方法:利用基因工程技术,将PTD基因与CML b3a2 bcr/abl基因融合并原核表达。将纯化的PTD—BCR/ABL融合蛋白与CML患者外周血单个核细胞(PBMC)体外共孵育,用流式细胞仪分别检测CD4^ 、CD8^ T细胞上活化抗原CD25的表达。结果:终浓度为100mg/L的PTD—BCR/ABL抗原体外刺激4d后,10例CML患者中,5例表现为CD8^ T细胞活化,2例表现为CD4^ T细胞活化,其中有1例CD8^ 和CD4^ T细胞同时活化;而作为对照的BCR/ABL抗原刺激组无一例表现为CD8^ 或CD4^ T细胞活化。结论:PTD能将外源性BCR/ABL抗原转导入抗原呈递细胞内,加工呈递后激活抗原特异性CD8^ 及CD4^ T细胞,为CML特异性CD8^ 、CD4^ T细胞的体外活化及细胞免疫治疗开辟一条新的途径。 相似文献
7.
Myoblasts fail to stimulate T cells but induce tolerance 总被引:1,自引:0,他引:1
Warrens Anthony N.; Zhang Jun Yan; Sidhu Sid; Watt Diana J; Lombardi Giovanna; Sewry Caroline A; Lechler Robert I. 《International immunology》1994,6(6):847-853
Recent interest in myoblast transfer and in the use of myoblastsas vehicles in gene therapy has made it important to understandthe potential immunogenicity of allogeneic or neoantlgen-expresslngmyoblasts. Given the problems of producing a pure populationof myoblasts, In this study we used a tumour-derived musclecell line (TE671), with phenotyplc features of myoblasts, whichwe transfected to express HLA-DR1. However, this cell line wasunable to stimulate either established HLA-DR1-specific alloreactlveT cell clones or a primary alloresponse. Nor could it presenthaemagglutlnln peptide HA 306–324 to DR1-restricted, HA306–324-speciflc T cell clones or lines. Indeed, prelncubatlonwith DR1-expressing TE671 and HA 306–324 rendered suchT cells tolerant as Judged by their subsequent inability toproliferate in response to a DR1+ B cell line plus peptide HA306–324. These results imply that myoblasts do not providecostlmulatory signals, and are therefore unlikely to stimulateallospeclfic T cells following myoblasts transplantation orto initiate neoantlgen-speclfic immune responses following Invivo transfection. 相似文献
8.
Mohty M Isnardon D Charbonnier A Lafage-Pochitaloff M Merlin M Sainty D Olive D Gaugler B 《International immunology》2002,14(7):741-750
Dendritic cells (DC) are a group of potent antigen-presenting cells (APC) specialized for initiating T cell immune responses. They originate from the bone marrow and upon stimulation with bacterial products, cytokines or CD40 ligation they acquire the ability to migrate to the secondary lymphoid organs. In vitro DC can be generated from human CD34(+) bone marrow cells and CD14(+) peripheral blood monocytes after culture with different cytokine combinations. Since most leukemic cells and tumors in general are devoid of APC capacities, various strategies have been used to increase their recognition and confer the capacity of antigen presentation on them. Because of our interest in the design of vaccine immunotherapy protocols for the adjuvant treatment of patients with lymphoid malignancies (LM), we chose to explore the capacity of human acute lymphoblastic leukemia, chronic lymphocytic leukemia and plasma cell leukemia to differentiate into cells with APC and DC features. Our results among a sample of 10 patients demonstrate that such approach is feasible. Leukemic cells could be induced in the presence of IL-4 and CD40L to exhibit a DC morphology with a phenotype of mature DC-like cells. They could also induce a potent proliferative response in naive CD4(+) T cells. In addition, they expressed chemokine receptor CCR7 and CD62L, and could drive T cells towards a T(h)1 response with secretion of IFN-gamma. Our strategy leading to increased LM cell immunogenicity may have potential clinical applications and LM appear to be attracting candidates for adjuvant vaccination and adoptive immunotherapy. 相似文献
9.
10.
Michael W. Konrad Anne L. Childs Thomas C. Merigan Ernest C. Borden 《Journal of clinical immunology》1987,7(5):365-375
Cancer patients were given a recombinant mutant interferon by alternating IM and IV injections with weekly escalation of doses from 0.1 to 400 million U. Antibodies specific to the interferon of the IgG class were detected in 24 of 30 patients using an indirect enzyme-linked immunosorbent assay. Serum from only 1 of the 30 patients had detectable ability to neutralize interferon biological activity. Thein vivo interferon serum level, assayed as antiviral activity immediately after IV injection, was not lower than levels seen in the absence of antibodies. Antibodies did not alter the kinetics of clearance of interferon from the serum after IV administration. Antibody levels progressively decreased when interferon administration was discontinued. In most patients antibody levels decreased during a maintenance period when interferon was being administered only by the IV route. In a subsequent trial interferon was given IV, and antibody developed in only 2 of 36 patients. In contrast, in a trial in which interferon was given IM, 20 of 25 patients developed antibody. No antibody-related clinical sequelae could be detected in any of these patients. 相似文献